IPSC vs MET · rev $6.6M vs P/E 13, $52.16B cap
Century Therapeutics Inc (IPSC) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Century Therapeutics Inc (IPSC) is a biotechnology company listed on US.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported IPSC revenue for 2024-12-31 was $6.6M. Net income was -$126.6M. Revenue was up 194.8% from 2023-12-31 to 2024-12-31. IPSC currently screens at market cap $47.8M.
MET does not have a complete income-statement cache yet.
IPSC currently screens at market cap $47.8M. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the IPSC and MET stock pages for the full models.
Not investment advice.